FDA’s second warning letter to Gilead

U.S. reg­u­lat­ors warned Gilead that it was down­play­ing teno­fo­vir’s risks. The FDA told Gilead that its sales reps had vi­ol­ated the law by giv­ing doc­tors and pa­tients false and mis­lead­ing in­form­a­tion that didn’t re­flect side ef­fects lis­ted on the drug la­bel.